Investor attention is shifting toward a key scientific conference as shares of biotechnology firm Veru Inc. trade quietly. The company is scheduled to deliver multiple presentations on its lead drug ...

Certain men face a far greater risk of prostate cancer – yet many will still not be routinely offered testing under new ...

Che-Kai Tsao, MD, MS, system chief of Solid Tumor Oncology at Northwell Health Cancer Institute, discusses new approaches ...

This satellite symposium at the European Society for Medical Oncology (ESMO) Congress 2025, chaired by Rana McKay, Professor ...

Congress 2025 took place in Berlin, Germany, a dynamic epicentre known for its blend of innovation, culture, and historical ...

Combined androgen blockade shows significant survival benefits over single-agent ADT in high-risk prostate cancer, as ...

Actinium Pharmaceuticals, Inc. , a leader in the development of differentiated targeted radiotherapies, today announced compelling preclinical data for ATNM-400, a first-in-class Actinium-225 (AC-225) ...